SCHEMBL93364

SCHEMBL93364

CN[C@@H](CCCNC(N)=O)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C3AR1 Q16581 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.40
FOLH1 Q04609 3/20 0.40
SHMT1 P34896 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KLK7 P49862 1/20 0.38
GAA P10253 1/20 0.38
CACNA1B Q00975 2/20 0.37
NOD1 Q9Y239 2/20 0.37
OTC P00480 1/20 0.36
POLB P06746 1/20 0.35
DDAH1 O94760 1/20 0.34
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
ITGB1 P05556 1/20 0.33
ITGA5 P08648 1/20 0.33
GNPAT O15228 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30404095 1.00 C3AR1 (0.47) C3AR1CTDSP1FOLH1SHMT1MEN1
SCHEMBL93363 1.00 C3AR1 (0.47) C3AR1CTDSP1FOLH1SHMT1MEN1
SCHEMBL25356845 0.95 FOLH1 (0.45) C3AR1CTDSP1FOLH1NOD1
SCHEMBL93490 0.95 FOLH1 (0.45) C3AR1CTDSP1FOLH1NOD1
SCHEMBL17769024 0.86 FOLH1 (0.38) C3AR1FOLH1MEN1KMT2AGAA
SCHEMBL27844592 0.86 C3AR1 (0.39) C3AR1CTDSP1FOLH1SHMT1MEN1
SCHEMBL93473 0.86 FOLH1 (0.38) C3AR1FOLH1MEN1KMT2AGAA
SCHEMBL1504531 0.86 FOLH1 (0.38) C3AR1CTDSP1FOLH1MEN1KMT2A
SCHEMBL5554963 0.86 C3AR1 (0.39) C3AR1CTDSP1FOLH1SHMT1MEN1
SCHEMBL162756 0.86 FOLH1 (0.38) C3AR1FOLH1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724457-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Rayzebio, Inc. (US) 2026-04-15 EP claimed
EP-4724459-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Peptidream Inc (JP) 2026-04-15 EP claimed
EP-4720087-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Zealand Pharma A/S (DK) 2026-04-08 EP claimed
EP-4720086-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Zealand Pharma A/S (DK) 2026-04-08 EP claimed
US-12521455-B2 Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof RADIONETICS ONCOLOGY, INC. (US) 2026-01-13 US claimed
WO-2025217074-A1 KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2025-10-16 WO claimed
WO-2024254339-A9 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF RAYZEBIO, INC. (US) 2025-10-16 WO claimed
US-20250312499-A1 KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2025-10-09 US claimed
WO-2024254339-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF RAYZEBIO, INC. (US) 2024-12-12 WO claimed
WO-2024252336-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF PEPTIDREAM INC. (JP) 2024-12-12 WO claimed
CN-115656161-A Phthalic dicarboxaldehyde disinfectant concentration detection indicator card and preparation method thereof 利康医药科技江苏有限公司 2023-01-31 CN claimed
WO-2022000043-A1 PEPTIDES AND USES THEREOF PreveCeutical Medical Inc. (CA) 2022-01-06 WO claimed
US-20160244484-A1 ANTI-INFLAMMATORY TRIPEPTIDES DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) 2016-08-25 US claimed
EP-3049428-A1 ANTI-INFLAMMATORY TRIPEPTIDES Dr. August Wolff GmbH & Co. KG Arzneimittel (DE) 2016-08-03 EP claimed
WO-2015040235-A1 ANTI-INFLAMMATORY TRIPEPTIDES DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) 2015-03-26 WO claimed
EP-1940452-B1 CGRP PEPTIDE ANTAGONISTS AND CONJUGATES AMGEN INC (US) 2012-11-21 EP claimed
WO-2012106469-A2 METHODS FOR TREATING INFECTIONS BY TARGETING MICROBIAL H2S-PRODUCING ENZYMES NEW YORK UNIVERSITY (US) 2012-08-09 WO claimed
US-20120172292-A1 METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE NEW YORK UNIVERSITY (US) 2012-07-05 US claimed
WO-2011032000-A2 METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE NEW YORK UNIVERSITY (US) 2011-03-17 WO claimed
WO-1996018405-A1 PREVENTING CONVERSION OF CITRULLINE TO ARGININOSUCCINATE TO LIMIT PATHOLOGICAL NITRIC OXIDE OVERPRODUCTION THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) 1996-06-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244484-A1 ANTI-INFLAMMATORY TRIPEPTIDES VIP, TNF, ENPEP C3AR1 260/4885CTDSP1 3038/4885FOLH1 173/4885
US-20120172292-A1 METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE NOS2, NOS1, NOS3 C3AR1 2929/4885CTDSP1 4402/4885FOLH1 1208/4885
US-20250312499-A1 KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF KISS1R, GNRHR, PROKR1 C3AR1 3214/4885CTDSP1 4005/4885FOLH1 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.